EliseAI, a company building AI agents for housing and healthcare operations, closed a $350 million funding round on September 29, 2026, at a $4 billion valuation, roughly doubling the $2.2 billion valuation it carried just 13 months earlier following an August 2025 raise. The round was led by Andreessen Horowitz and Bessemer Venture Partners, with participation from Ontario Teachers’ Pension Plan, Sapphire Ventures, and Navitas Capital, according to multiple reports including Fierce Healthcare and MobiHealthNews.
From Apartment Leasing to Healthcare Operations
EliseAI built its initial business automating leasing and resident communication for apartment operators, a product the company says now powers roughly one in six U.S. apartments. That footprint gave the company a large base of recurring enterprise customers before it expanded into healthcare operations, where it has applied similar conversational AI agents to administrative tasks like scheduling, intake, and patient communication rather than clinical decision-making. The company said it surpassed $200 million in annual recurring revenue in June 2026, a milestone that came before this latest round closed.
A Rapid Valuation Climb
The jump from a $2.2 billion valuation in August 2025 to $4 billion just over a year later reflects a broader pattern among AI infrastructure and vertical-agent startups that have posted fast revenue growth, where investors have been willing to pay a premium multiple for recurring revenue tied to AI automation rather than traditional SaaS subscriptions. Some reports note the Series F label applied to this round is based on company and investor characterization rather than a uniformly confirmed designation across all sources, following a $250 million Series E in August 2025.
Where the Money Is Going
EliseAI says it will use the new capital to accelerate product development and expand its deployment and sales teams, including opening a second engineering hub in San Francisco to complement its existing operations. The company has described its healthcare push specifically as still early relative to its housing business, suggesting the new funding is intended in part to close that gap by building out healthcare-specific product capabilities and sales coverage.
Competitive Pressure in Healthcare AI Agents
EliseAI’s healthcare expansion puts it in competition with a growing field of companies building administrative and operational AI tools for health systems, including ambient documentation and scheduling-focused startups that have themselves raised large rounds over the past two years. Unlike companies focused narrowly on clinical documentation, EliseAI’s pitch leans on its cross-industry agent infrastructure built originally for real estate, a strategy that bets shared underlying technology can be retooled across verticals faster than healthcare-native competitors can build similar breadth.
Skeptics and Supporters
Supporters of the round point to EliseAI’s revenue growth and existing enterprise distribution as evidence the company has found genuine product-market fit rather than relying purely on AI hype to justify its valuation. Skeptics of vertical-AI valuations more broadly have cautioned that administrative automation tools face lower switching costs and thinner moats than clinical software, since competitors can replicate scheduling or communication features more easily than diagnostic or decision-support tools that require regulatory clearance and clinical validation.
What’s Next
EliseAI has not disclosed a specific timeline for new healthcare product launches tied to this funding, though its stated plans to grow engineering and sales headcount suggest an acceleration is coming within the next several quarters. Whether the company’s housing-honed playbook translates cleanly to healthcare’s more regulated and clinically sensitive operating environment will likely determine whether its next valuation marker continues the rapid climb it has shown over the past year.
Photo: StartupStockPhotos / PIXABAY via Pixabay
